ALNY catalysts
Catalysts and events linked to ALNY, newest first.
ALNY stock catalysts and risks
Latest published review: 2026-10-21
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Alnylam is profitable but stock remains under pressure 2026-10-21 · Down | multiple compression via revenue-guidance cut and demand normalization | The decline is attributed to a revenue guidance cut for its drug Amvuttra due to demand normalization. | Not recorded |
Do these developments change your position?
Review ALNY alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-21Alnylam is profitable but stock remains under pressureALNY
- 2026-10-21Alnylam is profitable but stock remains under pressureALNY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.